Table 4.
Age- and multivariable-adjusted CRP values and migraine status relaxed criteria for men (i) and women (ii) The Reykjavik Study and Reykjavik Study for the Young
| i) Men | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | Average age and range |
Migraine status |
n | Age adjusted mg/l crp (95% CI) |
Migr. vs. No Migr. |
MO vs. MA |
MO vs. No Migr. |
Multivariable-adjusted mg/l crp (95% CI) |
Migr. vs. No Migr. |
MO vs. MA |
MO vs. No Migr. |
| Reykjavik | 27 | No Migr. | 513 | 0.57 (0.52, 0.63) | 0.61 (0.49, 0.76) | ||||||
| young | 19–34 | Migraine | 34 | 0.66 (0.46, 0.93) | P=0.47 | 0.68 (0.45, 1.01) | P=0.55 | ||||
| MO | 13 | 0.50 (0.28, 0.89) | P=0.24 | P=0.64 | 0.51 (0.28, 0.92) | P=0.19 | P=0.51 | ||||
| MA | 21 | 0.77 (0.49, 1.21) | 0.82 (0.50, 1.35) | ||||||||
| Reykjavik | 44 | No Migr. | 1168 | 1.14 (1.08, 1.21) | 0.71 (0.61, 0.83) | ||||||
| 35–49 | Migraine | 66 | 1.09 (0.87, 1.38) | P=0.72 | 0.67 (0.51, 0.88) | P=0.63 | |||||
| MO | 11 | 1.01 (0.56, 1.82) | P=0.77 | P=0.68 | 0.61 (0.34, 1.09) | P=0.70 | P=0.58 | ||||
| MA | 55 | 1.11 (0.86, 1.44) | 0.72 (0.56, 0.92) | ||||||||
| Reykjavik | 54 | No Migr. | 1856 | 1.30 (1.25, 1.36) | 0.74 (0.66, 0.84) | ||||||
| 50–59 | Migraine | 105 | 1.12 (0.93, 1.35) | P=0.12 | 0.69 (0.56, 0.84) | P=0.26 | |||||
| MO | 32 | 0.93 (0.66, 1.32) | P=0.20 | 0.06 | 0.62 (0.44, 0.87) | P=0.44 | P=0.26 | ||||
| MA | 73 | 1.21 (0.97, 1.52) | 0.72 (0.56, 0.92) | ||||||||
| Reykjavik | 66 | No Migr. | 924 | 1.56 (1.47, 1.66) | 1.16 (1.00, 1.36) | ||||||
| 60–79 | Migraine | 27 | 1.61 (1.14, 2.28) | P=0.86 | 1.26 (0.88, 1.82) | P=0.64 | |||||
| MO | 7 | 1.16 (0.57, 2.39) | P=0.30 | P=0.42 | 0.93 (0.45, 1.90) | P=0.26 | P=0.55 | ||||
| MA | 20 | 1.78 (1.19, 2.68) | 1.50 (0.97, 2.31) | ||||||||
| ii) Women | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | Average age and range |
Migraine status |
n | Age adjusted mg/l crp (95% CI) |
Migr. vs. No Migr. |
MO vs. MA |
MO vs. No Migr. |
Multivariable-adjusted mg/l crp (95% CI) |
Migr. vs. No Migr. |
MO vs. MA |
MO vs. No Migr. |
| Reykjavik | 27 | No Migr. | 530 | 0.78 (0.71, 0.86) | 0.81 (0.65, 1.01) | ||||||
| young | 19–34 | Migraine | 137 | 0.80 (0.67, 0.96) | P=0.83 | 0.87 (0.67, 1.13) | P=0.44 | ||||
| MO | 69 | 0.92 (0.71, 1.19) | P=0.13 | P=0.24 | 1.01 (0.74, 1.37) | P=0.08 | P=0.08 | ||||
| MA | 68 | 0.69 (0.53, 0.90) | 0.75 (0.55, 1.02) | ||||||||
| Reykjavik | 44 | No Migr. | 236 | 0.94 (0.80, 1.09) | 0.67 (0.50, 0.90) | ||||||
| 35–49 | Migraine | 60 | 0.81 (0.61, 1.07) | P=0.35 | 0.66 (0.46, 0.94) | P=0.96 | |||||
| MO | 21 | 0.72 (0.44, 1.16) | P=0.54 | P=0.24 | 0.60 (0.36, 0.98) | P=0.56 | P=0.63 | ||||
| MA | 39 | 0.86 (0.60, 1.22) | 0.70 (0.46, 1.07) | ||||||||
| Reykjavik | 54 | No Migr. | 716 | 1.09 (1.01, 1.18) | 0.73 (0.62, 0.87) | ||||||
| 50–59 | Migraine | 101 | 1.11 (0.91, 1.36) | P=0.86 | 0.78 (0.61, 0.99) | P=0.54 | |||||
| MO | 32 | 0.86 (0.60, 1.24) | P=0.09 | P=0.21 | 0.66 (0.46, 0.96) | P=0.24 | P=0.55 | ||||
| MA | 69 | 1.25 (0.98, 1.61) | 0.85 (0.63, 1.13) | ||||||||
| Reykjavik | 66 | No Migr. | 564 | 1.52 (1.40, 1.64) | 1.07 (0.87, 1.32) | ||||||
| 60–81 | Migraine | 50 | 1.32 (1.02, 1.71) | P=0.31 | 0.86 (0.63, 1.18) | P=0.11 | |||||
| MO | 12 | 0.87 (0.51, 1.49) | P=0.07 | P=0.04 | 0.52 (0.30, 0.91) | P=0.03 | P=0.007 | ||||
| MA | 38 | 1.51 (1.12, 2.04) | 1.01 (0.71, 1.43) | ||||||||
Migraine relaxed criteria defined answering yes to 2 or more out of 5 questions on migraine. Migr.: Migraine, MO: Migraine no aura, MA: Migraine and aura.
CRP, migraine status, age and gender in the Reykjavik Study and the Reykjavik Study for the Young using linear regression adjusting for case-control status, age, BMI, cholesterol, smoking, education, hormone use, diabetes mellitus, SBP and antihypertensive use. Each age category was analysed separately and subject with CRP values≥10 mg/l were excluded. Profile used in multivariable adjusted model was: control with average values for continuous variables, non-smoker, high school education, SBP between 130 and 160 mmHg, without: diabetes, hormone use and antihypertensive therapy. Women without birth control use.